The number of commercially insured Massachusetts residents whose health plans paid for a GLP-1 drug for weight loss dropped by an estimated 112,000 in the first quarter of 2026, a 52% decline from 2025, according to data previewed Sept. 17 by the Massachusetts Health Policy Commission. The drop followed decisions by several of the state's largest insurers to stop routinely covering drugs such as Wegovy and Zepbound for obesity.
The report counts insurance claims, not patient outcomes. It does not show how many of those residents stopped treatment, switched to paying cash, moved to cheaper compounded versions, or regained weight after losing access.
That gap matters to families. In 2025, patients paid an average of $78 a month in cost-sharing for weight-loss GLP-1s. Now many face a choice between paying hundreds of dollars out of pocket, stopping a drug that was working, or asking a clinician whether another diagnosis qualifies for coverage. Plans continue to cover GLP-1s for people with diabetes.
Insurer-by-Insurer Declines in Covered Weight-Loss Prescriptions
The commission, an independent state agency that monitors health care spending, analyzed commercial claims through March 2026. The findings will appear in the first annual report from its Office of Pharmaceutical Policy and Analysis, expected this winter.
The steepest changes came at the state's biggest carriers. At Blue Cross Blue Shield of Massachusetts, the largest insurer in the sample, 3.7% of members had a weight-loss GLP-1 covered in the first quarter, down from 6.1% in the last quarter of 2025, GBH News reported. Point32Health fell from 6.5% to 3.3%, and Health New England fell from 2.9% to 0.9%. Cigna and UnitedHealthcare, which started with much lower rates, barely changed.
Mass General Brigham Health Plan also ended routine coverage. MassHealth and the Group Insurance Commission, which covers state employees, stopped covering GLP-1s for weight loss beginning in July 2026, according to the commission. Those public plans are not part of the 52% figure.
The earlier surge explains why insurers acted. The estimated number of commercially insured residents using a GLP-1 for weight loss climbed from about 3,300 in 2019 to 216,000 in 2025, and spending on those prescriptions grew an average of 99.5% a year. Net commercial spending on all GLP-1 drugs reached about $1 billion in 2025.
Spending Falls as Insurers Return to Profit
The commission projects that commercial GLP-1 spending will fall to $662 million this year, closer to the $621 million spent in 2024, The Boston Globe reported. The two largest insurers have also rebounded. Blue Cross reported $53 million in operating income for the first half of 2026 after two years of losses, and Point32Health reported nearly $125 million after losing $96 million in the first half of 2025, according to the Globe.
Drug prices are moving, too. Average net prices for weight-loss GLP-1s, after manufacturer rebates and discounts, fell 43% between 2019 and early 2026, the commission found. It estimated that 2025 spending would have been 32% lower at Medicare-negotiated prices and 61% lower at the lowest international reference prices.
HPC Executive Director David Seltz said the drugs have shown value for patients but added, "At the same time, we must consider affordability and access." He pointed to rising patient cost sharing tied to fast-growing retail drug spending.
The Missing Data on Patients Who Lost Coverage
The biggest unanswered question is what happened to the roughly 112,000 people who dropped out of the claims data. The report does not track whether they kept taking the drugs by paying directly, which the Globe noted can cost from $150 to more than $400 a month.
"I do wonder a lot about what happened to those folks," Amanda Katchmar, a senior research analyst in the commission's Office of Pharmaceutical Policy and Analysis, told the Globe.
Cash-pay options have grown. Nationally, about one in six adults get GLP-1s through online direct-to-consumer channels, and self-pay accounts for 35% of Wegovy sales and 45% of Zepbound prescriptions, the commission said. Maintenance doses bought directly still cost about $4,188 a year for Wegovy and $5,388 for Zepbound. Compounded versions sold through some telehealth companies cost less, but they are not FDA-approved products.
The people most exposed are adults with obesity but no diabetes, lower-income patients who cannot absorb those prices, and workers whose employers declined to pay extra for optional GLP-1 coverage. About 27% of Massachusetts residents have obesity, according to state health data cited by the Globe. Without follow-up tracking, the state cannot yet measure whether lost access will later show up as higher costs for heart disease, diabetes, or joint problems.
Next Steps for Patients Facing a Coverage Gap
Patients who lost coverage can start by checking their plan's current formulary and asking their employer whether it bought optional GLP-1 coverage. They can also ask a clinician whether another diagnosis, such as type 2 diabetes, could qualify under plan rules and whether an appeal or prior authorization request is possible.
Anyone considering stopping a GLP-1 should talk with the prescribing clinician first. People buying online should use licensed pharmacies or manufacturer programs and avoid sellers that do not require a prescription. Some Medicare enrollees may qualify for the $50 GLP-1 Bridge program, which runs through 2027.
Relief may come on the price side. Massachusetts Health and Human Services Secretary Kiame Mahaniah predicted in March that GLP-1 prices could fall sharply within two years, GBH reported. The commission expects 12 new GLP-1 drugs to launch by 2030, though U.S. generics of today's blockbuster brands are not expected until 2041.
The commission will publish its full analysis this winter, and board materials are posted on the HPC meeting page. For now, the data show a clear drop in covered use, while the health and financial toll on people who lost coverage remains unmeasured.
Key Questions Answered
What did the Massachusetts report find? The Health Policy Commission estimated that 112,000 fewer commercially insured residents had a GLP-1 drug covered for weight loss in the first quarter of 2026, a 52% decline from 2025.
Which insurers cut coverage? Blue Cross Blue Shield of Massachusetts, Point32Health, and Mass General Brigham Health Plan were among the commercial plans that ended routine weight-loss coverage in 2026. MassHealth and the Group Insurance Commission followed in July.
Are GLP-1 drugs still covered for diabetes? Yes. The coverage changes apply to weight loss. Plans continue to cover GLP-1 drugs for people with diabetes.
Does the report show what happened to patients who lost coverage? No. It does not track whether patients paid out of pocket, switched to compounded drugs, stopped treatment, or regained weight.
How much does paying out of pocket cost? The Globe reported cash prices from about $150 to more than $400 a month. The commission put annual direct-to-consumer maintenance costs at $4,188 for Wegovy and $5,388 for Zepbound.
What should patients who lost coverage do? Review the plan formulary, ask about employer coverage options and appeals, and talk with the prescribing clinician before stopping or switching any medication.
